bioregulators

All articles tagged with “bioregulators”

Protocols

Insulin Sensitivity

Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses the insulin receptor entirely. The Khavinson bioregulators target β-cell regeneration via epigenetics. The three stories land at very different evidence grades — and the highest-impact decision in the whole class is sourcing.

Peptide therapy for insulin sensitivity now spans three distinct mechanistic classes: incretin agonists (GLP-1, tirzepatide, retatrutide) acting at the hormonal layer, mitochondrial-derived peptides (MOTS-c) acting at the cellular-energy layer via AMPK, and epigenetic bioregulators (Khavinson peptides, Pancragen) attempting to restore gene expression in β-cells. Weight loss explains only 13–21% of tirzepatide's HOMA-IR improvement — the rest is direct metabolic reprogramming. MOTS-c is an exercise mimetic in early trials. Bioregulators are a Russian-literature frontier awaiting Western replication. Sourcing is the biggest preventable harm in the whole class.

insulin sensitivitymetabolic healthtirzepatideGIPGLP-1+6

Immune HealthOutcome

Immune Regulation

The best immune peptides aren't the ones that turn the system up. They're the ones that teach it when to hold still.

Immune regulation is about homeostasis, not amplification. Thymosin Alpha-1 acts as a thermostat — pushing Th1 when the system is under-responsive, pushing T-regs when it's over-firing. Bioregulators work upstream at the level of gene expression. Thymosin Beta-4 regenerates across organ systems. Selank bridges the brain-immune axis. Understanding when to use each — and when not to — is the difference between peptide therapy and peptide tourism.

immune-health

Protocols

Metabolic HealthOutcome

Insulin Sensitivity

Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses the insulin receptor entirely. The Khavinson bioregulators target β-cell regeneration via epigenetics. The three stories land at very different evidence grades — and the highest-impact decision in the whole class is sourcing.

Peptide therapy for insulin sensitivity now spans three distinct mechanistic classes: incretin agonists (GLP-1, tirzepatide, retatrutide) acting at the hormonal layer, mitochondrial-derived peptides (MOTS-c) acting at the cellular-energy layer via AMPK, and epigenetic bioregulators (Khavinson peptides, Pancragen) attempting to restore gene expression in β-cells. Weight loss explains only 13–21% of tirzepatide's HOMA-IR improvement — the rest is direct metabolic reprogramming. MOTS-c is an exercise mimetic in early trials. Bioregulators are a Russian-literature frontier awaiting Western replication. Sourcing is the biggest preventable harm in the whole class.

insulin sensitivitymetabolic healthtirzepatideGIPGLP-1+6

Immune HealthOutcome

Immune Regulation

The best immune peptides aren't the ones that turn the system up. They're the ones that teach it when to hold still.

Immune regulation is about homeostasis, not amplification. Thymosin Alpha-1 acts as a thermostat — pushing Th1 when the system is under-responsive, pushing T-regs when it's over-firing. Bioregulators work upstream at the level of gene expression. Thymosin Beta-4 regenerates across organ systems. Selank bridges the brain-immune axis. Understanding when to use each — and when not to — is the difference between peptide therapy and peptide tourism.

immune-health

thymosin-alpha-1

thymosin-beta-4

bioregulators

selank

+2